| Dr Elizabeth F Jaffe, MD | |
|
53 Timber Ln, South Burlington, VT 05403-5201 | |
| (802) 864-0294 | |
| (802) 864-3779 |
| Full Name | Dr Elizabeth F Jaffe |
|---|---|
| Gender | Female |
| Speciality | Allergy & Immunology |
| Location | 53 Timber Ln, South Burlington, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013912468 | NPI | - | NPPES |
| 01744370 | Medicaid | NM | |
| 0VN1559 | Medicaid | VT | |
| 29424 | Other | VT | BLUE CROSS BLUE SHIELD VT |
| 321950 | Other | VT | MVP |
| 0369325-002 | Other | VT | CIGNA |
| 82X031 | Other | NY | BCBS NORTHEAST NEW YORK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 042-000-9472 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elizabeth F Jaffe, MD 53 Timber Ln, South Burlington, VT 05403-5201 Ph: (802) 864-0294 | Dr Elizabeth F Jaffe, MD 53 Timber Ln, South Burlington, VT 05403-5201 Ph: (802) 864-0294 |
News Archive
The University of Miami's College of Arts and Sciences and Miller School of Medicine were recently awarded a Howard Hughes Medical Institute grant to design and assess an innovative competency-based premedical curriculum in response to the 2009 American Association of Medical Colleges-Howard Hughes Medical Institute "Scientific Foundations for Future Physicians (SFFP)" report. The grant will be in collaboration with Purdue University, University of Maryland, Baltimore County, and University of Maryland at College Park.
Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.
One of the most basic yet least understood processes in our bodies is how cells crawl along tissues. This behavior is essential to the formation of an embryo and other processes, but it must be tightly controlled. A disturbance can lead to the spread of cancer cells or diseases like Spina bifida and Lissencephaly, in which cells fail to reach their proper destinations.
Huixin He, associate professor, nanoscale chemistry at Rutgers University, Newark, and Tamara Minko, professor at the Rutgers Ernest Mario School of Pharmacy, have developed a nanotechnology approach that potentially could eliminate the problems of side effects and drug resistance in the treatment of cancer. Under traditional chemotherapy, cancer cells, like bacteria, can develop resistance to drug therapy, leading to a relapse of the disease.
The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).
› Verified 3 days ago
Dr. Mark Lazarovich, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 53 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0294 Fax: 802-864-3779 | |
Dr. Edward F. Kent Jr., MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 53 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0294 Fax: 802-864-3779 |